Here’s What Boosted Alnylam Pharmaceuticals (ALNY) in Q3
Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Mid Cap Growth Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Alnylam Pharmaceuticals Inc. (ALNY)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Orbis Investment Management William B. Gray | 1,950,962 | $889,638,672 | -9% | 3.82% |
| 2. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 1,355,609 | $618,157,704 | +699% | 0.39% |
| 3. | Two Sigma Advisors John Overdeck And David Siegel | 892,500 | $406,980,000 | +236% | 0.81% |
| 4. | AQR Capital Management Cliff Asness | 744,008 | $336,009,047 | +296% | 0.22% |
| 5. | Millennium Management Israel Englander | 549,931 | $250,768,536 | +509% | 0.11% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $302.67 | 4 | $1,210.68 | 36 | 2024-10-17 | Filing | |
| $286.00 | 32 | $9,152.00 | 32 | 2024-08-29 | Filing | |
| $71.87 | 297,501 | $21,381,396.87 | 10,554,134 | 2017-05-31 | Filing | |
| $65.35 | 11,500 | $751,502.00 | 11,500 | 2017-05-30 | Filing | |
| $37.00 | 27,900 | $1,032,327.90 | 27,900 | 2016-10-13 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $463.08 | 295 | $136,608.60 | 21,264 | 2025-11-17 | Filing | |
| $461.96 | 323 | $149,213.08 | 21,559 | 2025-11-17 | Filing | |
| $460.84 | 707 | $325,813.88 | 21,882 | 2025-11-17 | Filing | |
| $459.89 | 622 | $286,051.58 | 22,589 | 2025-11-17 | Filing | |
| $458.41 | 794 | $363,977.54 | 23,211 | 2025-11-17 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 16,767,625 | $7,646,036,992 | 0.4% | |
| 2. | 16,434,253 | $7,493,808,123 | 1.02% | |
| 3. | 13,565,452 | $6,185,846,112 | 0.09% | |
| 4. | 9,903,601 | $4,516,042,243 | 0.08% | |
| 5. | 7,222,840 | $3,293,515,969 | 0.62% |
News See All
Alnylam Pharmaceuticals (ALNY) Surged on Strong Growth and Optimistic Revenue Outlook
ClearBridge Investments, an investment management company, released its “ClearBridge Mid Cap Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q3 2025 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen, and welcome to the Alnylam Pharmaceuticals 3Q 2025 Earnings Conference Call.
Alnylam (ALNY) Reports 238% Growth in Amvuttra Since February Launch, RBC Raises Price Target
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) ranks among the best biotech stocks to buy. RBC Capital maintained its Outperform rating for Alnylam Pharmaceuticals, Inc.
Wealth Enhancement Slashes Alnylam Pharmaceuticals, Inc. (ALNY) Stake by 64.5%
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is among the most promising biotech stocks to buy according to hedge funds.
7 Most Promising Biotech Stocks to Buy According to Hedge Funds
If there’s one sector that is gaining popularity each day, it’s definitely the biotechnology market.
Alnylam's AMVUTTRA Reduces GI Events in ATTR-CM Patients, According to New HELIOS-B Data
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is one of the best performing large cap stocks to buy.
Alnylam Pharmaceuticals, Inc. (ALNY) Reports $492M Amvuttra Sales, Raises 2025 Revenue Guidance
Alnylam Pharmaceuticals, Inc.
12 Best Performing Large Cap Stocks to Buy
Earlier on August 29, Bob Keiser, Aspire Strategist Portfolios co-chief investment officer and senior market strategist, joined CNBC's 'Closing Bell Overtime' to talk about the impact of a Fed cut on ...
14 Best Biotech Stocks to Buy Right Now
The biotech industry is almost always buzzing. However, there has been some unanticipated activity in this sector of late.
Hedge Fund Resource Center Billionaire Hedge Funds
